Pr Ir - Argenx NV CoFounder Officer

ARGX Stock  USD 611.18  3.01  0.49%   

Insider

Pr Ir is CoFounder Officer of argenx NV ADR
Age 64
Address Laarderhoogtweg 25, Amsterdam, Netherlands, 1101EB
Phone31 10 703 8441
Webhttps://www.argenx.com

Argenx NV Management Efficiency

At this time, Argenx NV's Return On Tangible Assets are fairly stable compared to the past year. Return On Assets is likely to rise to 0.14 in 2025, whereas Return On Capital Employed is likely to drop (0) in 2025. At this time, Argenx NV's Return On Assets are fairly stable compared to the past year. Asset Turnover is likely to rise to 0.38 in 2025, whereas Other Current Assets are likely to drop slightly above 114.2 M in 2025. Argenx NV's management efficiency ratios could be used to measure how well Argenx NV manages its routine affairs as well as how well it operates its assets and liabilities.
argenx NV ADR currently holds 20 M in liabilities with Debt to Equity (D/E) ratio of 0.0, which may suggest the company is not taking enough advantage from borrowing. argenx NV ADR has a current ratio of 10.85, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Argenx NV's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Lori CPALegend Biotech Corp
53
Jenna CohenBlueprint Medicines Corp
N/A
James MBAAmylyx Pharmaceuticals
58
JD MBABlueprint Medicines Corp
51
Grant MBAVaxcyte
57
MBA JDApellis Pharmaceuticals
52
DABT MDZai Lab
58
Jeff FairmanVaxcyte
60
Jaa RobersonDay One Biopharmaceuticals
N/A
Jens OkkelsAscendis Pharma AS
63
Peter HeermaTravere Therapeutics
53
Chris AielloAmylyx Pharmaceuticals
N/A
Justin KleeAmylyx Pharmaceuticals
34
Ann JDZai Lab
N/A
Mark VignolaTerns Pharmaceuticals
47
Ying DuZai Lab
59
Piyush JDAlnylam Pharmaceuticals
N/A
Tracey EsqBlueprint Medicines Corp
57
Tom HolmesAmylyx Pharmaceuticals
N/A
Alfred BoyleAlnylam Pharmaceuticals
N/A
Debra CannerAmylyx Pharmaceuticals
65
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Ltd, Universit Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands. Argenx Se is traded on NASDAQ Exchange in the United States. argenx NV ADR (ARGX) is traded on NASDAQ Exchange in USA. It is located in Laarderhoogtweg 25, Amsterdam, Netherlands, 1101EB and employs 15 people. Argenx NV is listed under Biotechnology category by Fama And French industry classification.

Management Performance

argenx NV ADR Leadership Team

Elected by the shareholders, the Argenx NV's board of directors comprises two types of representatives: Argenx NV inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Argenx. The board's role is to monitor Argenx NV's management team and ensure that shareholders' interests are well served. Argenx NV's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Argenx NV's outside directors are responsible for providing unbiased perspectives on the board's policies.
Karen Massey, Chief Officer
Beth DelGiacco, VP Relations
EMBA MBA, CEO Director
Filip Borgions, VP Operations
Arjen MSc, Vice Strategy
Karl Gubitz, Chief Officer
Luc Truyen, Chief Officer
Malini Moorthy, General Counsel
MSc EMBA, CEO CoFounder
Peter Ulrichts, Chief Officer
Pr Ir, CoFounder Officer
Keith Woods, Chief Officer
David MD, Advisor
Andria Wilk, Global Quality
Marc Schorpion, Global Resources

Argenx Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Argenx NV a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Argenx Stock Analysis

When running Argenx NV's price analysis, check to measure Argenx NV's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Argenx NV is operating at the current time. Most of Argenx NV's value examination focuses on studying past and present price action to predict the probability of Argenx NV's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Argenx NV's price. Additionally, you may evaluate how the addition of Argenx NV to your portfolios can decrease your overall portfolio volatility.